<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cabergoline: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cabergoline: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cabergoline: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11592" href="/d/html/11592.html" rel="external">see "Cabergoline: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866159"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Cabergoline [DSC];</li>
<li>APO-Cabergoline;</li>
<li>Dostinex</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F143967"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Ergot Derivative;</li>
<li>
                        Hyperprolactinemia Agent, Dopamine (D2) Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F143941"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: Safety:</b> Use the lowest effective dose; periodic monitoring for cardiac valve abnormalities (eg, echocardiogram) is suggested in patients receiving doses &gt;2 mg/<b>week</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25356808','lexi-content-ref-21296991']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25356808','lexi-content-ref-21296991'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="75f32ca4-cab6-48dd-9b89-a7bde464d597">Acromegaly</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acromegaly (off-label use):</b>
<b>Oral:</b> Initial: 0.25 to 0.5 mg two times per <b>week</b>; titrate as needed every 4 to 6 weeks based on insulin-like growth factor 1 (IGF-1) and growth hormone levels; usual dosage range: 0.5 to 3.5 mg/<b>week</b> (mean dose: ~2 mg/<b>week</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21846616','lexi-content-ref-9467544','lexi-content-ref-15272916','lexi-content-ref-18708434','lexi-content-ref-21104199']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21846616','lexi-content-ref-9467544','lexi-content-ref-15272916','lexi-content-ref-18708434','lexi-content-ref-21104199'])">Ref</a></span>). <b>Note:</b> Doses up to 7 mg/<b>week</b> have been studied in a small number of patients; doses &gt;2 mg/<b>week</b> may not be more efficacious in suppressing IGF-1 levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9467544','lexi-content-ref-18708434']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9467544','lexi-content-ref-18708434'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0b58b5af-6bad-40e2-96ee-0f42223a3654">Cushing disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cushing disease (off-label use):</b>
<b>Oral:</b> Initial: 0.5 mg administered once or twice <b>weekly</b>; may increase by 0.5 to 1 mg/<b>week</b> every 1 to 2 months until urinary free cortisol levels normalize; usual dosage range: 1 to 7 mg/<b>week </b>(median dose: ~2 to 3.5 mg/<b>week</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26222757','lexi-content-ref-20702648','lexi-content-ref-18957500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26222757','lexi-content-ref-20702648','lexi-content-ref-18957500'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="da5c02be-1f72-4f34-90ad-1e1ae190c1b7">Hyperprolactinemic disorders</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperprolactinemic disorders:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 0.25 to 0.5 mg/<b>week</b> administered in 1 or 2 divided <b>weekly </b>doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10852458','lexi-content-ref-11701688','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10852458','lexi-content-ref-11701688','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dosage adjustment: </i>May increase dose by 0.25 to 0.5 mg/<b>week </b>no sooner than every 4 weeks if needed based on serum prolactin levels (Di Sarno 2001; manufacturer's labeling); usual dosage range: 0.25 to 3 mg/<b>week </b>administered in 1 or 2 divided <b>weekly </b>doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11701688','lexi-content-ref-21296991','lexi-content-ref-18812485']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11701688','lexi-content-ref-21296991','lexi-content-ref-18812485'])">Ref</a></span>). If higher doses are used, may administer in as many as 3 to 4 divided <b>weekly</b> doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18812485']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18812485'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Duration of therapy: </i>Although the US labeling states that therapy may be discontinued after 6 months, treatment for ≥2 years has been recommended to reduce the risk of recurrence. Ensure that prolactin levels are normal and there is no visible tumor on MRI (in patients with prolactinoma) prior to tapering and discontinuing; maintenance of normal prolactin levels after tapering dosage to ≤0.5 mg/<b>week </b>may predict a lower risk of recurrence following discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21296991','lexi-content-ref-29043560']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21296991','lexi-content-ref-29043560'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="777600bf-198e-46fb-a3ee-c7c036f4221c">Lactation inhibition</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lactation inhibition (off-label use):</b>
<b>Oral:</b> 1 mg as a single dose within 48 hours postpartum (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33612017','lexi-content-ref-18302861','lexi-content-ref-Humphrey.2018','lexi-content-ref-Nisha.2009']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33612017','lexi-content-ref-18302861','lexi-content-ref-Humphrey.2018','lexi-content-ref-Nisha.2009'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990634"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, cabergoline pharmacokinetics are not altered in patients with moderate to severe renal impairment.</p></div>
<div class="block doha drugH1Div" id="F50987787"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution and monitor carefully in patients with severe hepatic impairment (Child-Pugh class C) (extensive hepatic metabolism).</p></div>
<div class="block dot drugH1Div" id="F56025325"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Cardiac valvulopathy: </b>Discontinue if an echocardiogram reveals new valvular regurgitation, valvular restriction, or valve leaflet thickening.</p></div>
<div class="block doe drugH1Div" id="F143942"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Start at the low end of the dosage range.</p></div>
<div class="block adr drugH1Div" id="F143916"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (27% to 29%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (15% to 17%), headache (26%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Dependent edema (1%), hypotension (≤1%), orthostatic hypotension (4%), palpitations (≤1%), peripheral edema (1%), syncope (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (≤1%), pruritus (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (5%), anorexia (≤1%), constipation (7% to 10%), diarrhea (≤2%), dyspepsia (2% to 5%), flatulence (≤2%), toothache (1%), vomiting (2% to 4%), xerostomia (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (≤1%), mastalgia (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (≤1%), asthenia (6%), depression (3%), drowsiness (≤2%), fatigue (5% to 7%), insomnia (≤1%), lack of concentration (1%), malaise (≤1%), nervousness (≤2%), pain (2%), paresthesia (≤2%), vertigo (1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Periorbital edema (1%), visual disturbance (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (≤1%), rhinitis (1%), throat irritation (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased libido (including hypersexuality), weight gain, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis, nasal congestion</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acquired valvular heart disease (Cawood 2009), constrictive pericarditis (Townsend 2004), coronary artery dissection (Mehta 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (Miwa 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Autoimmune hemolytic anemia (Gürbüz 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, impulse control disorder (Bulwer 2017), pathological gambling (Falhammar 2009), psychosis (Gupta 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pneumonitis (Frank 1999), pleural effusion (Belmonte 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fibrosis (extracardiac; including pericardial fibrosis, pleuropulmonary fibrosis, pulmonary fibrosis [Townsend 2004], retroperitoneal fibrosis)</p></div>
<div class="block coi drugH1Div" id="F143927"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known hypersensitivity to cabergoline, ergot derivatives, or any component of the formulation; uncontrolled hypertension; history of cardiac valvular disorders (indicated by valvulopathy of any valve, thickening of valve leaflet, valve restriction, or mixed valve restriction stenosis); history of pulmonary, pericardial, or retroperitoneal fibrotic disorders.</p></div>
<div class="block war drugH1Div" id="F143913"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:0em;display:inline">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac valvulopathy: Cardiac valvulopathy has been reported with use. Risk is increased with use of high doses (eg, &gt;2 mg/<b>day</b>). Although some conflicting data exist, a majority of observational evidence suggests the risk of valvulopathy in patients receiving typical low dose regimens (eg, ≤2 mg/<b>week</b>) is minimal or absent (Budayr 2020; ES [Katznelson 2014]; ES [Melmed 2011]; Stiles 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: Initial doses &gt;1 mg may cause orthostatic hypotension; may be symptomatic. Use with caution in patients with cardiovascular disease; hypertension, stroke, and seizure have been reported with other dopamine agonists. Concurrent use with antihypertensives may increase risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause somnolence, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pleural/retroperitoneal fibrosis: Cases of pleural, pericardial, and retroperitoneal fibrosis have been reported. Do not use in patients with a history of cardiac or extracardiac fibrotic disorders. Following diagnosis of fibrosis, discontinuation of cabergoline may result in improvement of condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric disorders: Aggression, psychotic behavior, and impulse control disorders such as pathological gambling, increased libido, hypersexuality, compulsive spending or buying, and binge-eating have been reported with use; generally reversible with dose reduction or discontinuation of treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution and carefully monitor patients with hepatic impairment; extensive hepatic metabolism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peptic ulcer disease: Use with caution in patients with peptic ulcer disease (PUD) or GI bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Raynaud syndrome: Use with caution in patients with Raynaud syndrome.</p></div>
<div class="block foc drugH1Div" id="F143922"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg</p></div>
<div class="block geq drugH1Div" id="F143909"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F143930"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Cabergoline Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $36.66</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866160"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dostinex: 0.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg</p></div>
<div class="block adm drugH1Div" id="F13267702"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with meals (may increase tolerability).</p></div>
<div class="block hazard drugH1Div" id="F49104437"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block use drugH1Div" id="F143923"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">
<b>Hyperprolactinemic disorders:</b> Treatment of hyperprolactinemic disorders, either idiopathic or caused by pituitary adenomas.</p></div>
<div class="block off-label drugH1Div" id="F25819768"><span class="drugH1">Use: Off-Label: Adult</span><p>Acromegaly; Cushing disease; Lactation inhibition</p></div>
<div class="block cyt drugH1Div" id="F13298921"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F143918"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents: Cabergoline may diminish the therapeutic effect of Antipsychotic Agents. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: Ergot Derivatives may enhance the adverse/toxic effect of Bromocriptine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: May increase the serum concentration of Cabergoline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dihydroergotamine: Ergot Derivatives may enhance the vasoconstricting effect of Dihydroergotamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the adverse/toxic effect of Ergot Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin (Withdrawn From US Market) may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methysergide: Ergot Derivatives may enhance the vasoconstricting effect of Methysergide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: Cabergoline may diminish the therapeutic effect of Metoclopramide. Metoclopramide may diminish the therapeutic effect of Cabergoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: Ergot Derivatives may enhance the serotonergic effect of Nefazodone. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: Cabergoline may diminish the therapeutic effect of Pipamperone [INT]. Pipamperone [INT] may diminish the therapeutic effect of Cabergoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Ergot Derivatives may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Cabergoline may diminish the therapeutic effect of Sulpiride. Sulpiride may diminish the therapeutic effect of Cabergoline. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49295128"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Cabergoline is approved for the treatment of hyperprolactinemic disorders. Increased prolactin concentrations due to a prolactinoma may cause galactorrhea, amenorrhea, oligomenorrhea or luteal phase insufficiency. Treatment with cabergoline may restore ovulatory cycles; fertility may return prior to regular menses (ES [Melmed 2011]; ESE [Luger 2021]). Cabergoline is also used off-label for the treatment of acromegaly; normalization of insulin-like growth factor 1 and growth hormone may also restore fertility in premenopausal patients with acromegaly.</p>
<p style="text-indent:0em;margin-top:2em;">Treatment with a dopamine agonist such as cabergoline is recommended for patients with a prolactinoma who are trying to conceive (ES [Melmed 2011]; ESE [Luger 2021]). Patients should be treated with the lowest dose possible until pregnancy is confirmed (ESE [Luger 2021]). Cabergoline may be used for patients with acromegaly who are trying to conceive; discontinue once pregnancy is confirmed (ESE [Luger 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">Normalizing prolactin concentrations during dopamine agonist treatment for a micro- or macroadenoma also improves fertility by restoring nocturnal penile tumescence, sperm count and sperm motility (ES [Melmed 2011]).</p></div>
<div class="block pri drugH1Div" id="F4116767"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Cabergoline is approved for the treatment of hyperprolactinemic disorders. Data related to the use of cabergoline for the treatment of hyperprolactinemia during pregnancy are available but limited compared to the use of other agents (Almistehi 2018; Auriemma 2013; Colao 2008; Lebbe 2010; Moltich 2015; Ricci 2002; Robert 1996; Stalldecker 2010). Although available evidence suggests cabergoline use early in pregnancy does not cause harm to the fetus, it is recommended that dopamine agonist therapy be discontinued once pregnancy is discovered (ES [Melmed 2011]; ESE [Luger 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">If treatment of a prolactinoma during pregnancy is required, a dopamine agonist such as cabergoline may be used. Serum prolactin concentrations are increased during pregnancy; monitoring prolactin levels may not be reliable for tumor progression (ES [Melmed 2011]; ESE [Luger 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">If treatment for acromegaly (off-label use) is required during pregnancy for worsening symptoms (such as headache) or evidence of tumor growth, use of cabergoline may be considered (ES [Katznelson 2014]). Monitoring of insulin-like growth factor 1 and/or growth hormone (GH) are not recommended during pregnancy as an active placental GH variant present in maternal blood limits the usefulness of the results (ES [Katznelson 2014]; ESE [Luger 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">Data related to cabergoline for the treatment of Cushing disease (off-label use) during pregnancy are limited. Medication may be considered for patients when surgery is not an option or for symptomatic control at initial diagnosis; agents other than cabergoline may be preferred (ES [Nieman 2015]; ESE [Luger 2021]; Nakhleh 2016; Sek 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Cabergoline is contraindicated in patients with uncontrolled hypertension; use is not recommended by the manufacturer in patients with pregnancy-induced hypertension (eg, preeclampsia, eclampsia, postpartum hypertension) unless benefit outweighs potential risk.</p></div>
<div class="block brc drugH1Div" id="F4116770"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if cabergoline is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Cabergoline interferes with lactation. When used for the treatment of hyperprolactinemic disorders (idiopathic or caused by pituitary adenomas), cabergoline should not be given to patients postpartum who are breastfeeding or who are planning to breastfeed.</p>
<p style="text-indent:-2em;margin-left:2em;">Cabergoline has been studied for maternal use immediately postpartum when the inhibition of physiologic lactation is needed for medical reasons (eg, stillbirth, death of the newborn, severe or acute maternal medical conditions) (Boucoiran 2021; Buhendwa 2008; Humphrey 2018; Nisha 2009). The Health and Human Services perinatal HIV guidelines suggest use of cabergoline may be considered for lactation inhibition in select patients with HIV infection (HHS [perinatal] 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">Cabergoline has also been studied for use in breastfeeding patients with an overabundant milk supply (hypergalactia) who do not respond to preferred therapies to reduce milk production. When used for this indication, breast milk should be discarded for ~5 days after using cabergoline (ABM [Johnson 2020]; Eglash 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, considering the importance of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F13267701"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take with food.</p></div>
<div class="block mop drugH1Div" id="F4117138"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Blood pressure (both sitting/supine and standing); serum prolactin level (monthly until normalized); erythrocyte sedimentation rate, chest x-ray, and serum creatinine (at baseline and during therapy as needed); signs and symptoms of pleuropulmonary disease, renal insufficiency, ureteral/abdominal vascular obstruction, and cardiac failure.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Echocardiogram:</i> Monitor as clinically indicated. Although the US labeling states that an echocardiogram should be done at baseline and every 6 to 12 months during therapy, current guidelines suggest that patients receiving doses ≤2 mg/<b>week</b> may not require routine echocardiography to monitor for cardiac valve abnormalities (ES [Katznelson 2014]; ES [Melmed 2011]).</p>
<p style="text-indent:-2em;margin-left:2em;">Acromegaly (off-label use): Insulin-like growth factor 1 (IGF-1), growth hormone, and prolactin every 4 to 6 weeks after dose adjustment then every 4 to 6 months after normalization of IGF-1 (AACE [Katznelson 2011]; Abs 1998; ACG [Melmed 2018]).</p>
<p style="text-indent:-2em;margin-left:2em;">Cushing disease (off-label use): Urinary free cortisol (24-hour) every 1 to 2 months during dose titration, then periodically (Godbout 2010; Pivonello 2009).</p></div>
<div class="block rer drugH1Div" id="F52042624"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Acromegaly (off-label use): Age-normalized serum insulin-like growth factor 1 (IGF-1) and a random growth hormone (GH) &lt;1 ng/mL (SI: &lt;1 mcg/L) correlate with disease control; consider targeting postoperative GH level &lt;0.4 ng/mL (SI: &lt;0.4 mcg/L) if ultra-sensitive GH assay is available; use of the same IGF-1 and GH assay in the same patient throughout management is suggested (ES [Katznelson 2014]; ACG [Melmed 2018]).</p></div>
<div class="block pha drugH1Div" id="F143912"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Cabergoline is a long acting dopamine receptor agonist with a high affinity for D<sub>2</sub> receptors; prolactin secretion by the anterior pituitary is predominantly under hypothalamic inhibitory control exerted through the release of dopamine. It is a potent 5-HT<sub>2B</sub>-receptor agonist, which may contribute to observed fibrotic/valvulopathic events.</p></div>
<div class="block phk drugH1Div" id="F143926"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Extensive, particularly to the pituitary </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 40% to 42% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Extensively hepatic via hydrolysis; minimal CYP mediated metabolism</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 63 to 69 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: 2 to 3 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Primarily feces (~60%); urine (~22%, &lt;4% as unchanged drug) </p></div>
<div class="block phksp drugH1Div" id="F51154228"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Patients with severe insufficiency (Child-Pugh score &gt;10) show a substantial increase in the mean cabergoline C<sub>max</sub> and AUC.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F143931"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Caberlex | Dostinex | Evadad</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cabaser | Caberpar | Cabertemis | Cabertrix | Dostinex | Lac stop | Lactamax | Triaspar</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cabaseril | Dostinex</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo cabergoline | Bergoline | Cabaser | Cobasol | Dostan | Dostinex | Tinexa</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Argolin | Caber | Cabergol | Caberol | Cabolac | Cabolin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cabergoline teva | Dostinex | Sostilar</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cabaser | Dostinex</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bergox | Caberedux | Cabergolina | Cabergolina germed pharma | Cabertrix | Dostinex</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cabaser | Dostinex</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cabertrix | Dostinex</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Alactin | Cabergolina | Cabertrix | Dostinex | Ergolin | Prolastat</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cabera | Dostinex</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cabaser | Cabaseril | Cabergolin 1A Pharma | Cabergolin AL | Cabergolin Beta | Cabergolin CT | Cabergolin Sandoz | Cabergolin stada | Cabergolin Teva | Cabergoline teva | Dostinex</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Cabertrix | Dostinex</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Cabergolina | Caberkana | Cabertrix | Dostinex | Lactinese | Prolactinox | Prolastat</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Dostinex</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cabergamoun | Cabrostinex | Delcabrin | Dostinex | Elonda | Golinosab | Golinotech | Hypolact | Jakaranda | Marvigoline | Nostifix | Remigoline</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cabergolina Teva | Dostinex | Sogilen</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Dostinex</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cabaser | Dostinex</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cabergoline sandoz | Cabergoline teva | Dostinex</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cabaser | Dostinex</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Dostinex</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Dostinex</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Dostinex</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cabergoline teva</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cabaser | Dostinex</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Cabaser | Cabotrim | Dostinex</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cabanine | Cabercet | Caberlact | Caberlin | Cabernorm | Cabgolin | Cabgon | Cabliz | Cablyn | Cabre | Cabtas | Calyn | Camforte | Cb Lin | Colette | Lactocab | Parcar | Zuricab</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Actualene | Cabaser | Cabergolina Rat | Dostinex</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Bergo | Dostinex | Lovista | Prolin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cabaser | Cabergoline Amel | Cabergoline Towa</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Caberlin | Dostinex | Nostifix</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Caverlactin | Dostinen | Dostinex</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Dostinex</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Dostinex | Proctin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cabaseril | Cabergolin AL | Cabergolin CT | Cabergolin rph | Cabergolin Sandoz | Cabergolin stada | Cabergolin Teva | Dostinex | Sogilen</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Dostinex | Sostilar</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cabergolin stada | Dostinex</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Dostinex</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Anuar | Anuar asf | Cabergolina | Caprolution | Dailet | Dostinex | Empercroz | Evemgleafem | Lacrastop | Logrecar | Omepisa | Perprolim | Progofhal | Sheldy | Trasgo | Vinreda</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Dostinex</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Dostinex | Synergo</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cabergoline fisher | Cabergoline medcor | Cabergoline PCH | Cabergoline sandoz | Dostinex</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cabaser | Dostinex</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Dostinex</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cabergol | Cabergolina | Cabernex | Dostinex | Lactinese | Promelac</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cabergoline teva | Dostinex</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Dostinex</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Dostinex</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Cabertrix</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Bergo | Dostinex | Lovista</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Dostinex</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Agalates | Bergolak | Dostinex</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Dostinex | Lovista | Nostifix</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cabaser | Cabergoline hexal | Cabergoline ratiopharm | Cabergoline sandoz | Dostinex | Kabergolin Ebb | Kabergolin ivax</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Dostinex</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cabergolina | Dostinex</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cabest | Dostinex</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cabergol | Caberlex | Dostinex | Prolact</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cabaser | Dostinex</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Dostinex</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Alactin | Caberlin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cabaser | Caberpar | Cabertrix | Dostinex | Neurodop</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alactin | Cabergolina | Caberguni | Dostinex | Prolastat</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Arigoline | Dostinex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9467544">
<a name="9467544"></a>Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. <i>J Clin Endocrinol Metab</i>. 1998;83(2):374-378. doi:10.1210/jcem.83.2.4556<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/9467544/pubmed" id="9467544" target="_blank">9467544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30159146">
<a name="30159146"></a>Almistehi WM, Almalki MH. Beat the giant: case of a giant prolactinoma during pregnancy on cabergoline. <i>Endocrinol Diabetes Metab Case Rep</i>. 2018;2018. pii: 18-0099. doi:10.1530/EDM-18-0099<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/30159146/pubmed" id="30159146" target="_blank">30159146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23162092">
<a name="23162092"></a>Auriemma RS, Perone Y, Di Sarno A, et al. Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. <i>J Clin Endocrinol Metab</i>. 2013;98(1):372-379. doi:10.1210/jc.2012-3039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/23162092/pubmed" id="23162092" target="_blank">23162092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851801">
<a name="22851801"></a>Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. <i>Sleep</i>. 2012;35(8):1039-1062.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/22851801/pubmed" id="22851801" target="_blank">22851801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19572029">
<a name="19572029"></a>Belmonte Y, de Fàbregues O, Marti M, Domingo C. Pleuropulmonary toxicity of another anti-Parkinson's drug: cabergoline. <i>Open Respir Med J</i>. 2009;3:90-93. doi:10.2174/1874306400903010090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/19572029/pubmed" id="19572029" target="_blank">19572029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33612017">
<a name="33612017"></a>Boucoiran I, Roy M, Poliquin V, et al. Evaluation of cabergoline for lactation inhibition in women living with HIV. <i>Int J STD AIDS</i>. 2021;32(7):654-661. doi:10.1177/0956462420984694<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/33612017/pubmed" id="33612017" target="_blank">33612017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16411066">
<a name="16411066"></a>Bronstein MD. Prolactinomas and Pregnancy. <i>Pituitary</i>. 2005;8(1):31-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/16411066/pubmed" id="16411066" target="_blank">16411066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32075620">
<a name="32075620"></a>Budayr A, Tan TC, Lo JC, et al. Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study. <i>BMC Endocr Disord</i>. 2020;20(1):25. doi:10.1186/s12902-020-0507-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/32075620/pubmed" id="32075620" target="_blank">32075620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18302861">
<a name="18302861"></a>Buhendwa L, Zachariah R, Teck R, et al. Cabergoline for suppression of puerperal lactation in a prevention of mother-to-child HIV-transmission programme in rural Malawi. <i>Trop Doct</i>. 2008;38(1):30-32. doi:10.1258/td.2007.060091<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/18302861/pubmed" id="18302861" target="_blank">18302861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28346715">
<a name="28346715"></a>Bulwer C, Conn R, Shankar A, et al. Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma. <i>Clin Endocrinol (Oxf)</i>. 2017;86(6):862-864. doi:10.1111/cen.13339<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/28346715/pubmed" id="28346715" target="_blank">28346715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cabergoline.1">
<a name="Cabergoline.1"></a>Cabergoline tablets, USP [prescribing information]. East Brunswick, NJ: Avet Pharmaceuticals Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19402868">
<a name="19402868"></a>Cawood TJ, Bridgman P, Hunter L, Cole D. Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma. <i>Intern Med J</i>. 2009;39(4):266-267. doi:10.1111/j.1445-5994.2009.01920.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/19402868/pubmed" id="19402868" target="_blank">19402868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17760883">
<a name="17760883"></a>Colao A, Abs R, Bárcena DG. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. <i>Clin Endocrinol (Oxf)</i>. 2008;68(1):66-71. doi:10.1111/j.1365-2265.2007.03000.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/17760883/pubmed" id="17760883" target="_blank">17760883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10852458">
<a name="10852458"></a>Colao A, Di Sarno A, Landi ML, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. <i>J Clin Endocrinol Metab</i>. 2000;85(6):2247-2252. doi:10.1210/jcem.85.6.6657<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/10852458/pubmed" id="10852458" target="_blank">10852458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15272916">
<a name="15272916"></a>Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. <i>Clin Endocrinol (Oxf)</i>. 2004;61(2):209-215. doi:10.1111/j.1365-2265.2004.02082.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/15272916/pubmed" id="15272916" target="_blank">15272916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11701688">
<a name="11701688"></a>Di Sarno A, Landi ML, Cappabianca P, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. <i>J Clin Endocrinol Metab</i>. 2001;86(11):5256-5261. doi:10.1210/jcem.86.11.8054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/11701688/pubmed" id="11701688" target="_blank">11701688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dostinex.1">
<a name="Dostinex.1"></a>Dostinex (cabergoline) [prescribing information]. New York, NY: Pfizer; August 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dostinex.2">
<a name="Dostinex.2"></a>Dostinex (cabergoline) [prescribing information]. New York, NY: Pfizer; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dostinex.3">
<a name="Dostinex.3"></a>Dostinex (cabergoline) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; July 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25361472">
<a name="25361472"></a>Eglash A. Treatment of maternal hypergalactia. <i>Breastfeed Med</i>. 2014;9(9):423-425. doi:10.1089/bfm.2014.0133<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/25361472/pubmed" id="25361472" target="_blank">25361472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-European.1">
<a name="European.1"></a>European Multicentre Study Group for Cabergoline in Lactation Inhibition. Single Dose Cabergoline Versus Bromocriptine in Inhibition of Puerperal Lactation: Randomised, Double-Blind, Multicentre Study. <i>BMJ</i>. 1991;302(6789):1367-1371.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19236300">
<a name="19236300"></a>Falhammar H, Yarker JY. Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. <i>Med J Aust</i>. 2009;190(2):97. doi:10.5694/j.1326-5377.2009.tb02289.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/19236300/pubmed" id="19236300" target="_blank">19236300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1642081">
<a name="1642081"></a>Ferrari C, Paracchi A, Mattei AM, et al. Cabergoline in the Long-Term Therapy of Hyperprolactinemic Disorders. <i>Acta Endocrinol (Copenh)</i>. 1992;126(6):489-494.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/1642081/pubmed" id="1642081" target="_blank">1642081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10573251">
<a name="10573251"></a>Frank W, Moritz R, Becke B, Pauli R. Low dose cabergoline induced interstitial pneumonitis. <i>Eur Respir J</i>. 1999;14(4):968-970. doi:10.1034/j.1399-3003.1999.14d40.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/10573251/pubmed" id="10573251" target="_blank">10573251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22937989">
<a name="22937989"></a>Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. <i>Eur J Neurol</i>. 2012;19(11):1385-1396.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/22937989/pubmed" id="22937989" target="_blank">22937989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20702648">
<a name="20702648"></a>Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A. Cabergoline monotherapy in the long-term treatment of Cushing's disease. <i>Eur J Endocrinol</i>. 2010;163(5):709-716. doi:10.1530/EJE-10-0382<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/20702648/pubmed" id="20702648" target="_blank">20702648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7911813">
<a name="7911813"></a>Giusti M, Porcella E, Carraro A, et al. A Cross-Over Study With the Two Novel Dopaminergic Drugs Cabergoline and Quinagolide in Hyperprolactinemic Patients. <i>J Endocrinol Invest</i>. 1994;17(1):51-57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/7911813/pubmed" id="7911813" target="_blank">7911813</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29482124">
<a name="29482124"></a>Gupta P, Tundup T, Singh J, Deb KS, Verma R, Kumar N. Treatment complexities in psychosis associated with cabergoline treatment in patients having pituitary prolactinomas. <i>Asian J Psychiatr</i>. 2018;31:129-132. doi:10.1016/j.ajp.2018.01.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/29482124/pubmed" id="29482124" target="_blank">29482124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23945126">
<a name="23945126"></a>Gürbüz F, Yağcı-Küpeli B, Kör Y, et al. The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma. <i>J Pediatr Endocrinol Metab</i>. 2014;27(1-2):159-163. doi:10.1515/jpem-2013-0151<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/23945126/pubmed" id="23945126" target="_blank">23945126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31285168">
<a name="31285168"></a>Harris K, Murphy KE, Horn D, MacGilivray J, Yudin MH. Safety of cabergoline for postpartum lactation inhibition or suppression: a systematic review [published online ahead of print, July 6, 2019]. <i>J Obstet Gynaecol Can</i>. 2019;S1701-2163(19)30304-4. doi:10.1016/j.jogc.2019.03.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/31285168/pubmed" id="31285168" target="_blank">31285168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Humphrey.2018">
<a name="Humphrey.2018"></a>Humphrey S, Baechler M, Schiff M et al. Cabergoline for lactation suppression among HIV+ and HIV- women. <i>Top Antivir Med</i>. 2018;26(suppl 1):362s.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32031417">
<a name="32031417"></a>Johnson HM, Eglash A, Mitchell KB, et al; Academy of Breastfeeding Medicine. ABM clinical protocol #32: management of hyperlactation. <i>Breastfeed Med</i>. 2020;15(3):129-134. doi:10.1089/bfm.2019.29141.hmj<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/32031417/pubmed" id="32031417" target="_blank">32031417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29520805">
<a name="29520805"></a>Kasuki L, Dalmolin MD, Wildemberg LE, Gadelha MR. Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands. <i>Clin Endocrinol (Oxf)</i>. 2018;88(6):889-895. doi:10.1111/cen.13595<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/29520805/pubmed" id="29520805" target="_blank">29520805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21846616">
<a name="21846616"></a>Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. <i>Endocr Pract</i>. 2011;17(suppl 4):1-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/21846616/pubmed" id="21846616" target="_blank">21846616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25356808">
<a name="25356808"></a>Katznelson L, Laws ER Jr, Melmed S, et al; Endocrine Society. Acromegaly: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2014;99(11):3933-3951. doi:10.1210/jc.2014-2700<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/25356808/pubmed" id="25356808" target="_blank">25356808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20455894">
<a name="20455894"></a>Lebbe M, Hubinont C, Bernard P, Maiter D. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. <i>Clin Endocrinol (Oxf)</i>. 2010;73(2):236-242. doi:10.1111/j.1365-2265.2010.03808.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/20455894/pubmed" id="20455894" target="_blank">20455894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34425558">
<a name="34425558"></a>Luger A, Broersen LHA, Biermasz NR, et al. ESE clinical practice guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. <i>Eur J Endocrinol</i>. 2021;185(3):G1-G33. doi:10.1530/EJE-21-0462<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/34425558/pubmed" id="34425558" target="_blank">34425558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22412238">
<a name="22412238"></a>Mehta NK, Malkani S, Ockene I. Spontaneous coronary artery dissection during cabergoline therapy. <i>Tex Heart Inst J</i>. 2012;39(1):92-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/22412238/pubmed" id="22412238" target="_blank">22412238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30050156">
<a name="30050156"></a>Melmed S, Bronstein MD, Chanson P, et al. A consensus statement on acromegaly therapeutic outcomes. <i>Nat Rev Endocrinol</i>. 2018;14(9):552-561. doi:10.1038/s41574-018-0058-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/30050156/pubmed" id="30050156" target="_blank">30050156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21296991">
<a name="21296991"></a>Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2011;96(2):273-288. doi:10.1210/jc.2010-1692<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/21296991/pubmed" id="21296991" target="_blank">21296991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14499208">
<a name="14499208"></a>Miwa H, Kondo T. Hair loss induced by dopamine agonist: case report and review of the literature. <i>Parkinsonism Relat Disord</i>. 2003;10(1):51-52. doi:10.1016/s1353-8020(03)00058-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/14499208/pubmed" id="14499208" target="_blank">14499208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25805896">
<a name="25805896"></a>Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. <i>Eur J Endocrinol</i>. 2015;172(5):R205-13. doi:10.1530/EJE-14-0848<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/25805896/pubmed" id="25805896" target="_blank">25805896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18708434">
<a name="18708434"></a>Moyes VJ, Metcalfe KA, Drake WM. Clinical use of cabergoline as primary and adjunctive treatment for acromegaly. <i>Eur J Endocrinol</i>. 2008;159(5):541-545. doi:10.1530/EJE-08-0306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/18708434/pubmed" id="18708434" target="_blank">18708434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27394707">
<a name="27394707"></a>Nakhleh A, Saiegh L, Reut M. Cabergoline treatment for recurrent Cushing's disease during pregnancy. <i>Hormones (Athens)</i>. 2016;15(3):453-458. doi:10.14310/horm.2002.1685<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/27394707/pubmed" id="27394707" target="_blank">27394707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26222757">
<a name="26222757"></a>Nieman LK, Biller BM, Findling JW, et al; Endocrine Society. Treatment of Cushing’s syndrome: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(8):2807-2831. doi:10.1210/jc.2015-1818<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/26222757/pubmed" id="26222757" target="_blank">26222757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nisha.2009">
<a name="Nisha.2009"></a>Nisha S, Uma S, Vineeta S. Role of newer drug cabergolin in lactation suppression as compared to estrogen-androgen combination. <i>J Obstet Gynecol India</i>. 2009;59(2):152-155.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16931508">
<a name="16931508"></a>Oertel WH, Benes H, Bodenschatz R, et al. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR). <i>Neurology</i>. 2006;67(6):1040-1046.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/16931508/pubmed" id="16931508" target="_blank">16931508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18812485">
<a name="18812485"></a>Ono M, Miki N, Kawamata T, et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. <i>J Clin Endocrinol Metab</i>. 2008;93(12):4721-4727. doi:10.1210/jc.2007-2758<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/18812485/pubmed" id="18812485" target="_blank">18812485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18957500">
<a name="18957500"></a>Pivonello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. <i>J Clin Endocrinol Metab</i>. 2009;94(1):223-230. doi:10.1210/jc.2008-1533<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/18957500/pubmed" id="18957500" target="_blank">18957500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7729332">
<a name="7729332"></a>Rains CP, Bryson HM, and Fitton A. Cabergoline: A Review of Its Pharmacological Properties and Therapeutic Potential in the Treatment of Hyperprolactinemia and Inhibition of Lactation. <i>Drugs</i>. 1995;49(2):255-279.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/7729332/pubmed" id="7729332" target="_blank">7729332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12401507">
<a name="12401507"></a>Ricci E, Parazzini F, Motta T, et al. Pregnancy Outcome After Cabergoline Treatment in Early Weeks of Gestation. <i>Reprod Toxicol</i>. 2002;16(6):791-793.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/12401507/pubmed" id="12401507" target="_blank">12401507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8829257">
<a name="8829257"></a>Robert E, Musatti L, Piscitelli G, et al. Pregnancy Outcome After Treatment With the Ergot Derivative, Cabergoline. <i>Reprod Toxicol</i>. 1996;10(4):333-337.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/8829257/pubmed" id="8829257" target="_blank">8829257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17202450">
<a name="17202450"></a>Roth BL. Drugs and Valvular Heart Disease. <i>N Engl J Med.</i> 2007;356(1):6-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/17202450/pubmed" id="17202450" target="_blank">17202450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17202453">
<a name="17202453"></a>Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. <i>N Engl J Med.</i> 2007;356(1):29-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/17202453/pubmed" id="17202453" target="_blank">17202453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21412893">
<a name="21412893"></a>Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M. Dopamine agonists for restless legs syndrome. <i>Cochrane Database Syst Rev</i>. 2011;(3):CD006009.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/21412893/pubmed" id="21412893" target="_blank">21412893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28710189">
<a name="28710189"></a>Sek KS, Deepak DS, Lee KO. Use of cabergoline for the management of persistent Cushing's disease in pregnancy. <i>BMJ Case Rep</i>. 2017;2017. pii: bcr-2016-217855. doi:10.1136/bcr-2016-217855<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/28710189/pubmed" id="28710189" target="_blank">28710189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20676778">
<a name="20676778"></a>Stalldecker G, Mallea-Gil MS, Guitelman M, et al. Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. <i>Pituitary</i>. 2010;13(4):345-350. doi:10.1007/s11102-010-0243-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/20676778/pubmed" id="20676778" target="_blank">20676778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15623686">
<a name="15623686"></a>Stiasny-Kolster K, Benes H, Peglau I, et al. Effective cabergoline treatment in idiopathic restless legs syndrome. <i>Neurology</i>. 2004;63(12):2272-2279.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/15623686/pubmed" id="15623686" target="_blank">15623686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33247916">
<a name="33247916"></a>Stiles CE, Lloyd G, Bhattacharyya S, et al. Incidence of cabergoline-associated valvulopathy in primary care patients with prolactinoma using hard cardiac endpoints. <i>J Clin Endocrinol Metab</i>. 2021;106(2):e711-e720. doi:10.1210/clinem/dgaa882<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/33247916/pubmed" id="33247916" target="_blank">33247916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15253989">
<a name="15253989"></a>Townsend M, MacIver DH. Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease. <i>Heart</i>. 2004;90(8):e47. doi:10.1136/hrt.2004.036236<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/15253989/pubmed" id="15253989" target="_blank">15253989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17274039">
<a name="17274039"></a>Trenkwalder C, Benes H, Grote L, et al. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. <i>Mov Disord</i>. 2007;22(5):696-703.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/17274039/pubmed" id="17274039" target="_blank">17274039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31183987">
<a name="31183987"></a>Tulloch KJ, Dodin P, Tremblay-Racine F, Elwood C, Money D, Boucoiran I. Cabergoline: a review of its use in the inhibition of lactation for women living with HIV. <i>J Int AIDS Soc</i>. 2019;22(6):e25322. doi:10.1002/jia2.25322<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/31183987/pubmed" id="31183987" target="_blank">31183987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-hhs.1">
<a name="hhs.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2019">
<a name="HHS.2019"></a>US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Perinatal_GL.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Perinatal_GL.pdf</a>. Updated January 31, 2023. Accessed February 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21104199">
<a name="21104199"></a>Vilar L, Azevedo MF, Naves LA, et al. Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR. <i>Pituitary</i>. 2011;14(2):148-156. doi:10.1007/s11102-010-0272-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/21104199/pubmed" id="21104199" target="_blank">21104199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7915824">
<a name="7915824"></a>Webster J, Piscitelli G, Polli A, et al. A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea. <i>N Engl J Med</i>. 1994;331(14):904-909.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/7915824/pubmed" id="7915824" target="_blank">7915824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1286524">
<a name="1286524"></a>Webster J, Piscitelli G, Polli A, et al. Dose-Dependent Suppression of Serum Prolactin by Cabergoline in Hyperprolactinaemia: A Placebo Controlled, Double Blind, Multicentre Study. <i>Clin Endocrinol (Oxf)</i>. 1992;37(6):534-541.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/1286524/pubmed" id="1286524" target="_blank">1286524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7900937">
<a name="7900937"></a>Webster J, Piscitelli G, Polli A, et al. The Efficacy and Tolerability of Long-Term Cabergoline Therapy in Hyperprolactinaemic Disorders: An Open, Uncontrolled, Multicentre Study. <i>Clin Endocrinol (Oxf)</i>. 1993;39(3):323-329.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/7900937/pubmed" id="7900937" target="_blank">7900937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27856776">
<a name="27856776"></a>Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: treatment of restless legs syndrome in adults: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology.</i> 2016;87(24):2585-2593. doi:10.1212/WNL.0000000000003388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/27856776/pubmed" id="27856776" target="_blank">27856776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29043560">
<a name="29043560"></a>Xia MY, Lou XH, Lin SJ, Wu ZB. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. <i>Endocrine</i>. 2018;59(1):50-61. doi:10.1007/s12020-017-1444-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/29043560/pubmed" id="29043560" target="_blank">29043560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17202454">
<a name="17202454"></a>Zanettini R, Antonini A, Gatto G, et al. Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson’s Disease. <i>N Engl J Med. </i>2007;356(1):39-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/17202454/pubmed" id="17202454" target="_blank">17202454</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8600 Version 279.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
